Astellas Pharma and Pfizer amended the protocol of the international Phase 3 PROSPER trial evaluating Xtandi (enzalutamide) in men with non–metastatic castration–resistant prostate cancer (CRPC). PROSPER is a randomized, double–blind, placebo–controlled trial (NCT02003924) that is evaluating the ... Read more